| First Author | Rehg JE | Year | 2008 |
| Journal | Comp Med | Volume | 58 |
| Issue | 3 | Pages | 246-52 |
| PubMed ID | 18589866 | Mgi Jnum | J:140432 |
| Mgi Id | MGI:3813776 | Citation | Rehg JE, et al. (2008) Utility of antiPax5 in the diagnosis of lymphoproliferative disorders and neoplasia in mice. Comp Med 58(3):246-52 |
| abstractText | CD45R/B220 antigen (B220) is a common mouse panB-cell marker used for paraffin-embedded tissues. However, antiB220 has limited specificity in diagnostic pathology because the B220 antigen is expressed on subsets of cytotoxic T lymphocytes and natural killer cells, on plasmacytic dendritic cells, and on T lymphocytes of mice with the lymphoproliferative disorder associated with Fas (lymphoproliferative mutant mouse, B6.MRL-Fas(lpr/J)) or Fas ligand (generalized lymphoproliferative disease mutant mouse, C3H/ HeJ-Fasl(gld/J) or B6Smn.C3-Fasl(gld/J)). In addition, mouse B lymphocytes vary in the amount of B220 expressed, and some subsets of mouse B lymphocytes do not express B220 at all. In comparison, Pax5 expression (detected by immunohistochemistry using antiPax5) offers greater specificity and sensitivity because of its earlier expression during B-cell differentiation, its ability to detect all committed B cells, and its restriction to the B-cell lineage. Here we describe the use of an antibody to human Pax5 in diagnostic pathology with formalin-fixed, paraffin-embedded mouse tissue. |
